Size: 30 Capsules

Category: Probiotics

Product Number: 103005

Product Code: FEM

Usage: Take 1 capsule daily for maintenance and increase to 2 capsules a day as needed, or use as directed by your qualified health care consultant.

fem-dophilus® contains two patented and clinically documented probiotic strains, Lactobacillus rhamnosus GR-1™ and Lactobacillus reuteri RC-14®, discovered and developed by Dr. Gregor Reid and Dr. Andrew Bruce at Urex Biotech. Over 20 years of research supports the oral use of GR-1™ and RC-14® to colonize and protect the vaginal tract.*

Clinical trials have shown that GR-1™ and RC-14®:

Help to maintain or restore healthy vaginal flora which is important in maintaining vaginal health*

Support the health of the urinary tract*

fem-dophilus® is manufactured under pharmaceutical GMP conditions with guaranteed potency and consistency. The probiotic strains in fem-dophilus® are in a proprietary polysaccharide matrix, which protects the bacteria from stomach acid and enhances probiotic bacteria survival to the lower intestine.

Keep Refrigerated

Keep out of the reach of children.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Ingredients:

Total probiotic bacteria 5 billion cfu

Lactobacillus rhamnosus GR-1™

Lactobacillus reuteri RC-14®

Other Ingredients: Dextrose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate (vegetable source).

Capsule consists of gelatin and titanium dioxide.

Contains: Dairy (casein, in trace amounts)No wheat, no gluten, no soy, no egg, no fish/shellfish, no nuts/tree nuts.

Research has confirmed that oral supplementation with friendly probiotic bacteria is important for many health reasons. Users of other Jarrow Formulas’ probiotics products such as Jarro-Dophilus EPS™ are already aware of the many health benefits that can be experienced from supplementing with beneficial bacteria, i.e. probiotics. Less well-known is the fact that specific strains of probiotic bacteria active in the digestive tract also contribute to vaginal health.*

It has been established that women with an unbalanced intestinal microflora profile are at a higher risk of developing unbalanced urogenital microflora as well (i.e. Lactobacilli-deficient vaginal microflora). Researchers have shown that good vaginal health is associated with a Lactobacilli-dominantvaginal microflora. Fortunately, scientific findings have documented that oral supplementation with probiotic strains GR-1™ and RC-14® taken by mouth at the rate of one capsule per day resulted in vaginal colonization within one week, and significant results were observed within four weeks in terms of an increase in “friendly” Lactobacilli organisms and a reduction in less desirable flora. In clinical trials, this has translated to positive reports by the probiotic-supplemented subjects regarding their vaginal health at rates twice those found with placebo.*

Protection from Stomach Acids*In order for an oral probiotic capsule to be effective, significant numbers of live bacteria (indicated as Colony Forming Units or CFU) must survive through the stomach and upper intestinal tract to the lower intestine where probiotic bacteria exert their full benefits. Fem-Dophilus® incorporates a proprietary polysaccharide matrix that protects the beneficial bacteria from gastric acids and bile during the journey through the stomach into the intestinal tract.*

CLINICAL STUDY

The major criteria required in selecting beneficial probiotic strains for urogenital health are their ability to colonize the vagina and reduce undesirable vaginal microflora.In one trial, GR-1™ and RC-14® administered in skim milk were given orally to 10 women twice daily for 14 days. GR-1™ and RC-14® were recovered from the vagina and identified by morphology and molecular typing within one week of commencement of the trial, thus demonstrating that these strains, when taken orally, are able to colonize the vaginal tract within 7 days of initial intake.1In another randomized, placebo-controlled trial, GR-1™ and RC-14® were given to 64 women for 60 days. Microscopy analysis showed the restoration of healthy vaginal flora in 37% of women taking GR-1™ and RC-14® vs. 13% in subjects in placebo group.2

Retail Price 24.95